BioElectronics Corp. $BIEL News Last updated 12/
Post# of 273249
Posted On: 12/26/2016 5:31:16 AM
BioElectronics Corp. $BIEL News
Last updated 12/26/2016 - 0.0004
BioElectronics' ActiPatch(R) Nonprescription Medical Device That Reduces Pain 52% and Medication Use 50% including Opioids
Dec 12, 2016
Service
-
BioElectronics' ActiPatch(R) Nonprescription Medical Device That Reduces Pain 52% and Medication Use 50% including Opioids
Study Published in the Pain Management Medical Journal
FREDERICK, MD--(Marketwired - Dec 12, 2016) - BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com the maker of ActiPatch®, an advanced over-the-counter medical device, announced the publication of a clinical study, An Over-the-counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use & Their Adverse Effects, report which indicates that ActiPatch® Therapy is effective for mitigating chronic back pain and reducing medication use including opioids. This peer reviewed article has been published in the distinguished medical journal of Pain Management, and is available at
http://www.futuremedicine.com/doi/pdf/10.2217/pmt-2016-0046
ActiPatch Musculoskeletal Pain Therapy is a drug-free, wearable nonprescription medical device that provides 720 hours of flexible on/off therapy for under $30.00 retail, or $.04 per hour.
Chronic pain affects an estimated 1.5 billion people worldwide, with back pain being the most prevalent form. The 7-day ActiPatch registry study of 1,394 back pain sufferers was based in the UK. Baseline pain was 8.04 on a 10-point visual analog scale, or severe pain, with mean pain duration of 6.1 years. High baseline pain was present despite the use of an average 2.5 pain medications per subject, with 71% being prescriptions, including 40% using opiate-based prescription pain medications. More than 60% of the participants reported less than adequate pain relief and 66% experienced adverse side effects from pain medications.
ActiPatch reduced baseline pain, on average, by 39.9%, with 52% experiencing a ≥40% pain reduction averaging 66% from baseline. In addition, 50% of the subjects were able to reduce or eliminate analgesic medication use including those using opiate-based medications.
"In this study group, the use of ActiPatch® not only reduced pain for the majority of individuals but had the added benefit of reducing analgesic medication use and improving overall quality of life in just 7 days," said Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics Corporation. "Therefore we believe these results have important implications for the future of pain management."
BioElectronics has collected data from a total of 12,390 assessments over a two year period from subjects who trialed ActiPatch® in the UK with consistent results. A prior registry study of 5000 general chronic pain subjects was previously published - A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/pdf/10.2217/pmt.15.35
These study results are included in the data BioElectronics has submitted to the FDA for its additional indication of use for nonprescription market clearance for the treatment of musculoskeletal pain.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; and Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings, Inc.
732-335-1152
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics Appoints Southeast Asia Distributor
Nov 01, 2016
Service
-
BioElectronics Appoints Southeast Asia Distributor
FREDERICK, MD--(Marketwired - Nov 1, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced consumer pain management medical devices, today announced that it has appointed PharmEvo https://www.pharmevo.biz as its ActiPatch® Musculoskeletal Pain Therapy distributor for Vietnam, Kenya, Cambodia, Myanmar, Kenya and Sri Lanka.
PharmEvo was established in 1999, has a sales team of 850 people, and annual sales of over $300 million. Corporate headquarters are in Karachi, Pakistan with 9 locations in Pakistan and international market coverage in Vietnam, Cambodia, Kenya, Philippines, Myanmar, Sri Lanka, Guatemala, Kenya, Tanzania, Pakistan, Kazakhstan, and Uzbekistan. PharmEvo engaged in the creation, development, manufacture and marketing of pharmaceutical products, including over-the-counter (OTC) medicines, medical equipment and infant formulas. PharmEvo partners with the following international groups for bringing best quality products to its consumers: Bioton (Poland), Lactalis (France), Omron (Japan), Becton Dickson (USA), etc.
Nadeem Rehmat, Director of PharmaEvo Business Development has expressed his confidence that ActiPatch Musculoskeletal drug-free inexpensive pain therapy is a great fit to their OTC line.
"We are pleased to have PharmEvo selling our ActiPatch products in Southeast Asia. We believe our unique cost effective drug-free pain therapy will have excellent market acceptance in Asia," said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic wounds and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Edward Whelan
732 335 1152
EdTWhelan@BIELCorp.com
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
Oct 27, 2016
Service
-
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, and its award winning "Best OTC Marketing Campaign on a Small Budget"
FREDERICK, MD--(Marketwired - Oct 27, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced nonprescription disposable $30.00 neuromodulation pain relief medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://westbrookradio.com/2016/10/26/andrew-w...corp-biel/
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning "Best OTC Marketing Campaign on a Small Budget," and its assessment of 12,000+ users and the exceptional product acceptance.
Chronic Pain - 20% of adults globally suffers from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide that modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton's short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.
Demonstrated Marketability to Consumers - The Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.
Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they "intended" to or would "maybe" purchase. 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.
A leading pain management medical journal Pain Management published a 5,000+ subject study: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.221...5.35. The data demonstrates a consistent clinically meaningful effect in chronic musculoskeletal pain from a variety of causes (osteoarthritis, rheumatoid arthritis, fibromyalgia, post-surgical, neuropathic) affecting different regions of the body (back, hip, knee, wrist, elbow, and shoulder).
Additionally, our 6 month Observation Study demonstrates:
Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.
Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.
Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity, and 71% reported their quality of life was much better to a great deal better.
Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the doctor and pain specialist.
Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.
Side effects: None reported
US FDA OTC Market Clearance - The Company has submitted a 510(k) pre market application to the FDA with three ActiPatch randomized clinical trials. Additionally, the clinical trials evidence is being supplemented with a Registry of a 5,600 consumer assessment on back pain, a 6-Month Observational Study on product durability, a Medication Use Reduction Study and a Sleep Improvement Study.
Mr. Whelan also explained the technology's significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video on how it works.
Grace Holdings, Inc.
732-335-1152
EdTWhelan@BIELCorp.com
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics Comments on its U.S. FDA's OTC Market Clearance Application
Oct 10, 2016
Service
-
BioElectronics Comments on its U.S. FDA's OTC Market Clearance Application
PR Newswire
FREDERICK, Md., Oct. 10, 2016
FREDERICK, Md., Oct. 10, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced disposable electroceutical devices, announced that on Monday, October 3rd, 2016 it met with senior management from the FDA's Division of Neurological and Physical Medicine Devices, including the Deputy Division Director, the Acting Branch Chief of the Physical Medicine and Neurotherapeutic Devices Branch, the three reviewers for the ActiPatch® Musculoskeletal Pain Therapy 51O(k) premarket notification, and the assigned statistician, to discuss the data requirements to support a musculoskeletal pain indication for the device.
In the 51O(k) premarket notification for the ActiPatch® Musculoskeletal Pain Therapy, we included our osteoarthritis of the knee and plantar fasciitis clinical studies, along with an explanation of the device's mechanism of action, to support the indication for musculoskeletal pain relief. The agency has requested clinical data from an additional anatomical application area. We are prepared to provide real world evidence showing use of the ActiPatch® for treatment of chronic back pain from our large UK chronic pain registry. The Agency is assessing whether the registry data, along with the two well controlled clinical studies mentioned above, would be sufficient to support a musculoskeletal pain indication, and FDA has defined certain criteria that it considers relevant to this assessment; we are preparing to submit the relevant information for the agency's review. The original UK Registry was published in Pain Management A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35
We have data on 5,660 back pain users, further supported by new data from an Observational Study on 117 subjects who used the ActiPatch® therapy over a 6-month period.
"We are hopeful that the data will meet the Agency's acceptance criteria and will expedite over-the-counter market clearance for musculoskeletal pain relief," said Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics Corporation.
About BioElectronics Corporation
BioElectronics Corporation develops non-invasive electroceutical devices and is the maker of an industry leading family of disposable, drug-free, pain therapy devices: RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-comments-on-its-us-fdas-otc-market-clearance-application-300341599.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' ActiPatch® Drug-free Pain Therapy to be Featured at Pharmacy Week in Trinidad & Tobago W.I.
Oct 03, 2016
Service
-
BioElectronics' ActiPatch® Drug-free Pain Therapy to be Featured at Pharmacy Week in Trinidad & Tobago W.I.
PR Newswire
FREDERICK, Md., Oct. 3, 2016
FREDERICK, Md., Oct. 3, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulation medical devices, is pleased to announce that ActiPatch will be the featured new product at Pharmacy Week, October 16th to the 23rd by SuperPharm Limited www.superpharmtt.com the leading Trinidad and Tobago pharmacy chain.
"Our pharmacists focus on patient-centered pharmaceutical care and are an integral part of our health care services. We are excited to offer our patients pain consultations on the therapeutic benefits and safety of drug-free ActiPatch relief therapy," said Danielle Gale, R.Ph, SuperPharm's Category Manager – Pharmaceuticals.
"We are pleased to have SuperPharm stores carrying our ActiPatch products on their shelves." We had several excellent training sessions with their pharmacists and they are excited to recommend our products to their consumers," said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-drug-free-pain-therapy-to-be-featured-at-pharmacy-week-in-trinidad--tobago-wi-300337598.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics Submits Back Pain Relief & Medication Use Side Effects Registry Study for Publication
Sep 28, 2016
Service
-
BioElectronics Submits Back Pain Relief & Medication Use Side Effects Registry Study for Publication
PR Newswire
FREDERICK, Md., Sept. 28, 2016
FREDERICK, Md., Sept. 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulation medical devices announced that it has submitted a paper: "ActiPatch© Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief & Analgesic Adverse Effects" for publication. The study reports that the majority of chronic back pain sufferers have less than adequate pain relief and significant side effects from their use of nonprescription and prescription analgesic drugs, including opiates, which impact quality of life. ActiPatch© use decreased chronic back pain such that the majority of subjects were able to eliminate or reduce their analgesic drug use.
The Company's prior research published in Pain Management of 5,000+ users' results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35, was one of the Top 5 articles read out of all of the 28 Future Science Group Journals in 2106. Future Science Group is a progressive publisher focused on breakthrough medical biotechnological and scientific research.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-submits-back-pain-relief--medication-use-side-effects-registry-study-for-publication-300335240.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics Launches ActiPatch®, Musculoskeletal Pain Therapy In Sweden
Sep 13, 2016
Service
-
BioElectronics Launches ActiPatch®, Musculoskeletal Pain Therapy In Sweden
PR Newswire
FREDERICK, Md., Sept.13, 2016
FREDERICK, Md., Sept.13, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that its Sweden distributor, Harmony Health, Sweden, AB , has received initial stocking orders for Pharmacy Heart, www.apotekhjartat.se and the Life health products chain, www.lifebutiken.se. Life health products are a chain of 220 stores and Pharmacy Heart has 400 stores.
"This product launch will give us good market coverage for the 3+ million chronic pain sufferers in Sweden. We shipped the first order last week and have scheduled orders for the remainder of this year," Said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-launches-actipatch-musculoskeletal-pain-therapy-in-sweden-300326766.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' Drug-free ActiPatch® Pain Therapy
Apr 28, 2016
Service
-
BioElectronics' Drug-free ActiPatch® Pain Therapy
Highlighted in UK's Express Newspaper on Dangers of Excessive Drug Use
PR Newswire
FREDERICK, Md., April 28, 2016
FREDERICK, Md., April 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its drug-free ActiPatch® product was noted in the United Kingdom's Express Newspaper Health Section, http://www.express.co.uk/life-style/health/664330/arthritis-pain-pills-warning-sufferers-taking-too-many-drugs-fight-agony. The paper has a circulation of 400,000 that will increase the awareness of ActiPatch therapy for arthritis and chronic pain.
The article entitled "Arthritis pain pills warning: Sufferers taking too many drugs to fight agony" describes the recent Arthritis Research UK/Daily Telegraph survey reveals the severe impact of pain and excessive drug use among the 8.5 million Britons now suffering from arthritis. The Arthritis Research UK survey showed the following:
Fewer than half (46%) feel satisfied with the current pain treatment they are receiving from their GP or healthcare professional.
The vast majority (76%) say the pain prevents them from living life to the full.
A huge number (80%) say their mobility is affected.
More than three in five (64%) report problems sleeping because of pain.
The article notes ActiPatch's drug-free mechanism of action and its effectiveness in reducing pain, which improves quality life with less dependence on strong painkillers.
ActiPatch is clinically proven treatment for osteoarthritis as demonstrated in an independently conducted double blind, placebo-controlled, randomized clinical trial, which was published in the peer, reviewed journal Rheumatology (www.rheumatology.oxfordjournals.org). There was a reported statistically significant reduction in pain and a significant improvement in the WOMAC² index. In addition, patients in the treatment group reported a statistically significant reduction in NSAID compared to the placebo group.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-drug-free-actipatch-pain-therapy-300259047.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' ActiPatch® Chronic Pain Therapy Featured In UK's Leading Daily Mail Newspaper Health Section
Apr 25, 2016
Service
-
BioElectronics' ActiPatch® Chronic Pain Therapy Featured In UK's Leading Daily Mail Newspaper Health Section
PR Newswire
FREDERICK, Md., April 25, 2016
FREDERICK, Md., April 25, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its ActiPatch® product's were featured in the United Kingdom's leading Daily Mail's Sunday Health Section, http://www.dailymail.co.uk/health/article-355...etics.html. The paper has a circulation of 1.7 million and should increase the awareness of ActiPatch and its benefits for the millions of UK's chronic pain sufferers.
The article, entitled "The £20 pulsing skin patch that could end the misery of chronic pain for arthritis sufferers and diabetics" describes the devices unique technology and reports on the Company's new follow-up Observational Study. The 6-Month study of 254 men and women with different types of chronic pain suggest that it can be highly effective and lead to improved quality life and less dependence on strong painkillers. More than 90% had continued relief averaging a 61% reduction in pain, and nine out of ten had improved sleep. Some 89% were more physically active, 86% reduced their medication use, including prescription opioids, and 65% said they spent less money on over-the-counter painkillers.
The study has been accepted and will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK https://www.britishpainsociety.org/2016-asm/.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-chronic-pain-therapy-featured-in-uks-leading-daily-mail-newspaper-health-section-300256531.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics President Interviewed by the StockRadio.com
Apr 11, 2016
Service
-
BioElectronics President Interviewed by the StockRadio.com
Discusses Bioelectronics Mitigation of Chronic Pain and Drug Use
PR Newswire
FREDERICK, Md., April 11, 2016
FREDERICK, Md., April 11, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://thestockradio.com/andrew-whelan-bioele...-2953.html.
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning "Best OTC Marketing Campaign on a Small Budget," and its assessment of 10,000+ users and the exceptional product acceptance.
Chronic Pain 20% of adults globally suffer from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide. Chronic pain modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.
Demonstrated Marketability to Consumers the Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.
Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they "intended" to or would "maybe" purchase and 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.
A leading pain management medical journal Pain Management published our 5,000+ subject study: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 The data demonstrates a consistent clinically meaningful effect in chronic musculoskeletal pain from a variety of causes (osteoarthritis, rheumatoid arthritis, fibromyalgia, post-surgical, neuropathic) affecting different regions of the body (back, hip, knee, wrist, elbow, and shoulder).
Additionally, our 6 month Observation Study demonstrates:
Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.
Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.
Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity, and 71% reported their quality of life was much better to a great deal better.
Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the Doctor and Pain Specialist.
Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.
Side effects: None reported
US FDA OTC Market Clearance: The Company has submitted a 510(k) pre market application to the FDA with statistically significant and clinically meaningful pain reduction data in the three ActiPatch randomized clinical trials. Additionally, the clinical trials evidence has been supplemented with 10,000 consumer assessments and the Observational Study data on treatment durability, medication use and costs.
Mr. Whelan also explained the technology's significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video on how it works.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-president-interviewed-by-the-stockradiocom-300248990.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
Last updated 12/26/2016 - 0.0004
BioElectronics' ActiPatch(R) Nonprescription Medical Device That Reduces Pain 52% and Medication Use 50% including Opioids
Dec 12, 2016
Service
-
BioElectronics' ActiPatch(R) Nonprescription Medical Device That Reduces Pain 52% and Medication Use 50% including Opioids
Study Published in the Pain Management Medical Journal
FREDERICK, MD--(Marketwired - Dec 12, 2016) - BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com the maker of ActiPatch®, an advanced over-the-counter medical device, announced the publication of a clinical study, An Over-the-counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use & Their Adverse Effects, report which indicates that ActiPatch® Therapy is effective for mitigating chronic back pain and reducing medication use including opioids. This peer reviewed article has been published in the distinguished medical journal of Pain Management, and is available at
http://www.futuremedicine.com/doi/pdf/10.2217/pmt-2016-0046
ActiPatch Musculoskeletal Pain Therapy is a drug-free, wearable nonprescription medical device that provides 720 hours of flexible on/off therapy for under $30.00 retail, or $.04 per hour.
Chronic pain affects an estimated 1.5 billion people worldwide, with back pain being the most prevalent form. The 7-day ActiPatch registry study of 1,394 back pain sufferers was based in the UK. Baseline pain was 8.04 on a 10-point visual analog scale, or severe pain, with mean pain duration of 6.1 years. High baseline pain was present despite the use of an average 2.5 pain medications per subject, with 71% being prescriptions, including 40% using opiate-based prescription pain medications. More than 60% of the participants reported less than adequate pain relief and 66% experienced adverse side effects from pain medications.
ActiPatch reduced baseline pain, on average, by 39.9%, with 52% experiencing a ≥40% pain reduction averaging 66% from baseline. In addition, 50% of the subjects were able to reduce or eliminate analgesic medication use including those using opiate-based medications.
"In this study group, the use of ActiPatch® not only reduced pain for the majority of individuals but had the added benefit of reducing analgesic medication use and improving overall quality of life in just 7 days," said Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics Corporation. "Therefore we believe these results have important implications for the future of pain management."
BioElectronics has collected data from a total of 12,390 assessments over a two year period from subjects who trialed ActiPatch® in the UK with consistent results. A prior registry study of 5000 general chronic pain subjects was previously published - A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/pdf/10.2217/pmt.15.35
These study results are included in the data BioElectronics has submitted to the FDA for its additional indication of use for nonprescription market clearance for the treatment of musculoskeletal pain.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; and Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings, Inc.
732-335-1152
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics Appoints Southeast Asia Distributor
Nov 01, 2016
Service
-
BioElectronics Appoints Southeast Asia Distributor
FREDERICK, MD--(Marketwired - Nov 1, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced consumer pain management medical devices, today announced that it has appointed PharmEvo https://www.pharmevo.biz as its ActiPatch® Musculoskeletal Pain Therapy distributor for Vietnam, Kenya, Cambodia, Myanmar, Kenya and Sri Lanka.
PharmEvo was established in 1999, has a sales team of 850 people, and annual sales of over $300 million. Corporate headquarters are in Karachi, Pakistan with 9 locations in Pakistan and international market coverage in Vietnam, Cambodia, Kenya, Philippines, Myanmar, Sri Lanka, Guatemala, Kenya, Tanzania, Pakistan, Kazakhstan, and Uzbekistan. PharmEvo engaged in the creation, development, manufacture and marketing of pharmaceutical products, including over-the-counter (OTC) medicines, medical equipment and infant formulas. PharmEvo partners with the following international groups for bringing best quality products to its consumers: Bioton (Poland), Lactalis (France), Omron (Japan), Becton Dickson (USA), etc.
Nadeem Rehmat, Director of PharmaEvo Business Development has expressed his confidence that ActiPatch Musculoskeletal drug-free inexpensive pain therapy is a great fit to their OTC line.
"We are pleased to have PharmEvo selling our ActiPatch products in Southeast Asia. We believe our unique cost effective drug-free pain therapy will have excellent market acceptance in Asia," said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic wounds and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Edward Whelan
732 335 1152
EdTWhelan@BIELCorp.com
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
Oct 27, 2016
Service
-
BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, and its award winning "Best OTC Marketing Campaign on a Small Budget"
FREDERICK, MD--(Marketwired - Oct 27, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced nonprescription disposable $30.00 neuromodulation pain relief medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://westbrookradio.com/2016/10/26/andrew-w...corp-biel/
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning "Best OTC Marketing Campaign on a Small Budget," and its assessment of 12,000+ users and the exceptional product acceptance.
Chronic Pain - 20% of adults globally suffers from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide that modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton's short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.
Demonstrated Marketability to Consumers - The Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.
Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they "intended" to or would "maybe" purchase. 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.
A leading pain management medical journal Pain Management published a 5,000+ subject study: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.221...5.35. The data demonstrates a consistent clinically meaningful effect in chronic musculoskeletal pain from a variety of causes (osteoarthritis, rheumatoid arthritis, fibromyalgia, post-surgical, neuropathic) affecting different regions of the body (back, hip, knee, wrist, elbow, and shoulder).
Additionally, our 6 month Observation Study demonstrates:
Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.
Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.
Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity, and 71% reported their quality of life was much better to a great deal better.
Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the doctor and pain specialist.
Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.
Side effects: None reported
US FDA OTC Market Clearance - The Company has submitted a 510(k) pre market application to the FDA with three ActiPatch randomized clinical trials. Additionally, the clinical trials evidence is being supplemented with a Registry of a 5,600 consumer assessment on back pain, a 6-Month Observational Study on product durability, a Medication Use Reduction Study and a Sleep Improvement Study.
Mr. Whelan also explained the technology's significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video on how it works.
Grace Holdings, Inc.
732-335-1152
EdTWhelan@BIELCorp.com
Copyright © 2016 Marketwired. All Rights Reserved
BioElectronics Comments on its U.S. FDA's OTC Market Clearance Application
Oct 10, 2016
Service
-
BioElectronics Comments on its U.S. FDA's OTC Market Clearance Application
PR Newswire
FREDERICK, Md., Oct. 10, 2016
FREDERICK, Md., Oct. 10, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced disposable electroceutical devices, announced that on Monday, October 3rd, 2016 it met with senior management from the FDA's Division of Neurological and Physical Medicine Devices, including the Deputy Division Director, the Acting Branch Chief of the Physical Medicine and Neurotherapeutic Devices Branch, the three reviewers for the ActiPatch® Musculoskeletal Pain Therapy 51O(k) premarket notification, and the assigned statistician, to discuss the data requirements to support a musculoskeletal pain indication for the device.
In the 51O(k) premarket notification for the ActiPatch® Musculoskeletal Pain Therapy, we included our osteoarthritis of the knee and plantar fasciitis clinical studies, along with an explanation of the device's mechanism of action, to support the indication for musculoskeletal pain relief. The agency has requested clinical data from an additional anatomical application area. We are prepared to provide real world evidence showing use of the ActiPatch® for treatment of chronic back pain from our large UK chronic pain registry. The Agency is assessing whether the registry data, along with the two well controlled clinical studies mentioned above, would be sufficient to support a musculoskeletal pain indication, and FDA has defined certain criteria that it considers relevant to this assessment; we are preparing to submit the relevant information for the agency's review. The original UK Registry was published in Pain Management A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35
We have data on 5,660 back pain users, further supported by new data from an Observational Study on 117 subjects who used the ActiPatch® therapy over a 6-month period.
"We are hopeful that the data will meet the Agency's acceptance criteria and will expedite over-the-counter market clearance for musculoskeletal pain relief," said Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics Corporation.
About BioElectronics Corporation
BioElectronics Corporation develops non-invasive electroceutical devices and is the maker of an industry leading family of disposable, drug-free, pain therapy devices: RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-comments-on-its-us-fdas-otc-market-clearance-application-300341599.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' ActiPatch® Drug-free Pain Therapy to be Featured at Pharmacy Week in Trinidad & Tobago W.I.
Oct 03, 2016
Service
-
BioElectronics' ActiPatch® Drug-free Pain Therapy to be Featured at Pharmacy Week in Trinidad & Tobago W.I.
PR Newswire
FREDERICK, Md., Oct. 3, 2016
FREDERICK, Md., Oct. 3, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulation medical devices, is pleased to announce that ActiPatch will be the featured new product at Pharmacy Week, October 16th to the 23rd by SuperPharm Limited www.superpharmtt.com the leading Trinidad and Tobago pharmacy chain.
"Our pharmacists focus on patient-centered pharmaceutical care and are an integral part of our health care services. We are excited to offer our patients pain consultations on the therapeutic benefits and safety of drug-free ActiPatch relief therapy," said Danielle Gale, R.Ph, SuperPharm's Category Manager – Pharmaceuticals.
"We are pleased to have SuperPharm stores carrying our ActiPatch products on their shelves." We had several excellent training sessions with their pharmacists and they are excited to recommend our products to their consumers," said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-drug-free-pain-therapy-to-be-featured-at-pharmacy-week-in-trinidad--tobago-wi-300337598.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics Submits Back Pain Relief & Medication Use Side Effects Registry Study for Publication
Sep 28, 2016
Service
-
BioElectronics Submits Back Pain Relief & Medication Use Side Effects Registry Study for Publication
PR Newswire
FREDERICK, Md., Sept. 28, 2016
FREDERICK, Md., Sept. 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulation medical devices announced that it has submitted a paper: "ActiPatch© Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief & Analgesic Adverse Effects" for publication. The study reports that the majority of chronic back pain sufferers have less than adequate pain relief and significant side effects from their use of nonprescription and prescription analgesic drugs, including opiates, which impact quality of life. ActiPatch© use decreased chronic back pain such that the majority of subjects were able to eliminate or reduce their analgesic drug use.
The Company's prior research published in Pain Management of 5,000+ users' results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35, was one of the Top 5 articles read out of all of the 28 Future Science Group Journals in 2106. Future Science Group is a progressive publisher focused on breakthrough medical biotechnological and scientific research.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-submits-back-pain-relief--medication-use-side-effects-registry-study-for-publication-300335240.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics Launches ActiPatch®, Musculoskeletal Pain Therapy In Sweden
Sep 13, 2016
Service
-
BioElectronics Launches ActiPatch®, Musculoskeletal Pain Therapy In Sweden
PR Newswire
FREDERICK, Md., Sept.13, 2016
FREDERICK, Md., Sept.13, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that its Sweden distributor, Harmony Health, Sweden, AB , has received initial stocking orders for Pharmacy Heart, www.apotekhjartat.se and the Life health products chain, www.lifebutiken.se. Life health products are a chain of 220 stores and Pharmacy Heart has 400 stores.
"This product launch will give us good market coverage for the 3+ million chronic pain sufferers in Sweden. We shipped the first order last week and have scheduled orders for the remainder of this year," Said Erin Sanders, BioElectronics Sales Manager.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Grace Holdings
732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-launches-actipatch-musculoskeletal-pain-therapy-in-sweden-300326766.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' Drug-free ActiPatch® Pain Therapy
Apr 28, 2016
Service
-
BioElectronics' Drug-free ActiPatch® Pain Therapy
Highlighted in UK's Express Newspaper on Dangers of Excessive Drug Use
PR Newswire
FREDERICK, Md., April 28, 2016
FREDERICK, Md., April 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its drug-free ActiPatch® product was noted in the United Kingdom's Express Newspaper Health Section, http://www.express.co.uk/life-style/health/664330/arthritis-pain-pills-warning-sufferers-taking-too-many-drugs-fight-agony. The paper has a circulation of 400,000 that will increase the awareness of ActiPatch therapy for arthritis and chronic pain.
The article entitled "Arthritis pain pills warning: Sufferers taking too many drugs to fight agony" describes the recent Arthritis Research UK/Daily Telegraph survey reveals the severe impact of pain and excessive drug use among the 8.5 million Britons now suffering from arthritis. The Arthritis Research UK survey showed the following:
Fewer than half (46%) feel satisfied with the current pain treatment they are receiving from their GP or healthcare professional.
The vast majority (76%) say the pain prevents them from living life to the full.
A huge number (80%) say their mobility is affected.
More than three in five (64%) report problems sleeping because of pain.
The article notes ActiPatch's drug-free mechanism of action and its effectiveness in reducing pain, which improves quality life with less dependence on strong painkillers.
ActiPatch is clinically proven treatment for osteoarthritis as demonstrated in an independently conducted double blind, placebo-controlled, randomized clinical trial, which was published in the peer, reviewed journal Rheumatology (www.rheumatology.oxfordjournals.org). There was a reported statistically significant reduction in pain and a significant improvement in the WOMAC² index. In addition, patients in the treatment group reported a statistically significant reduction in NSAID compared to the placebo group.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-drug-free-actipatch-pain-therapy-300259047.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics' ActiPatch® Chronic Pain Therapy Featured In UK's Leading Daily Mail Newspaper Health Section
Apr 25, 2016
Service
-
BioElectronics' ActiPatch® Chronic Pain Therapy Featured In UK's Leading Daily Mail Newspaper Health Section
PR Newswire
FREDERICK, Md., April 25, 2016
FREDERICK, Md., April 25, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its ActiPatch® product's were featured in the United Kingdom's leading Daily Mail's Sunday Health Section, http://www.dailymail.co.uk/health/article-355...etics.html. The paper has a circulation of 1.7 million and should increase the awareness of ActiPatch and its benefits for the millions of UK's chronic pain sufferers.
The article, entitled "The £20 pulsing skin patch that could end the misery of chronic pain for arthritis sufferers and diabetics" describes the devices unique technology and reports on the Company's new follow-up Observational Study. The 6-Month study of 254 men and women with different types of chronic pain suggest that it can be highly effective and lead to improved quality life and less dependence on strong painkillers. More than 90% had continued relief averaging a 61% reduction in pain, and nine out of ten had improved sleep. Some 89% were more physically active, 86% reduced their medication use, including prescription opioids, and 65% said they spent less money on over-the-counter painkillers.
The study has been accepted and will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK https://www.britishpainsociety.org/2016-asm/.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-chronic-pain-therapy-featured-in-uks-leading-daily-mail-newspaper-health-section-300256531.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
BioElectronics President Interviewed by the StockRadio.com
Apr 11, 2016
Service
-
BioElectronics President Interviewed by the StockRadio.com
Discusses Bioelectronics Mitigation of Chronic Pain and Drug Use
PR Newswire
FREDERICK, Md., April 11, 2016
FREDERICK, Md., April 11, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://thestockradio.com/andrew-whelan-bioele...-2953.html.
Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching product portfolio, its award winning "Best OTC Marketing Campaign on a Small Budget," and its assessment of 10,000+ users and the exceptional product acceptance.
Chronic Pain 20% of adults globally suffer from chronic pain. This market is larger than diabetes, heart disease, and cancer combined. ActiPatch is a nonprescription medical device that addresses the unmet need for 1.5 billion chronic pain sufferers worldwide. Chronic pain modifies the way the central nervous system works. The modification results in an increase in pain perception from less provocation. ActiPatch modulates the body's nerve activity to dampen the pain perception, thereby mitigating the use of drugs. Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, New York State University Binghamton short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.
Demonstrated Marketability to Consumers the Company's Try and Tell sales and marketing campaign has won this year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. ActiPatch therapy is the leading analgesic in Walgreens/Boots in the UK.
Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they "intended" to or would "maybe" purchase and 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.
A leading pain management medical journal Pain Management published our 5,000+ subject study: A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 The data demonstrates a consistent clinically meaningful effect in chronic musculoskeletal pain from a variety of causes (osteoarthritis, rheumatoid arthritis, fibromyalgia, post-surgical, neuropathic) affecting different regions of the body (back, hip, knee, wrist, elbow, and shoulder).
Additionally, our 6 month Observation Study demonstrates:
Treatment durability: Over 90% of the participants reported continued relief averaging a 61% reduction in pain even after six months.
Decreased medication use: 86% reported a decrease in medication use that continued to improve over time. Most importantly, this decrease included prescription narcotic based drugs.
Improved quality of life: 90% reported improved sleep, 89% reported greater physical activity, and 71% reported their quality of life was much better to a great deal better.
Healthcare savings: 65% spent less on pain therapies and 65% reported fewer visits to the Doctor and Pain Specialist.
Decreased adverse events from medication use: 68% were experiencing adverse side effects, of these 71% reported a reduction in adverse side effects.
Side effects: None reported
US FDA OTC Market Clearance: The Company has submitted a 510(k) pre market application to the FDA with statistically significant and clinically meaningful pain reduction data in the three ActiPatch randomized clinical trials. Additionally, the clinical trials evidence has been supplemented with 10,000 consumer assessments and the Observational Study data on treatment durability, medication use and costs.
Mr. Whelan also explained the technology's significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video on how it works.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-president-interviewed-by-the-stockradiocom-300248990.html
SOURCE BioElectronics Corporation
Copyright © 2016 PR Newswire. All Rights Reserved
(0)
(0)Scroll down for more posts ▼